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Primary brain tumors are presently classified based on imaging and histopathological techniques, which
remains unsatisfaying. We profiled here by quantitative real time PCR (qRT-PCR) the transcripts of
eighteen histone deacetylases (HDACs) and a subset of transcriptional co-factors in non-tumoral brain
samples from 15 patients operated for epilepsia and in brain tumor samples from 50 patients diagnosedwith
grade II oligodendrogliomas (ODII, n 5 9), grade III oligodendrogliomas (ODIII, n 5 22) and
glioblastomas (GL, n 5 19). Co-factor transcripts were significantly different in tumors as compared to
non-tumoral samples and distinguished differentmolecular subgroups of brain tumors, regardless of tumor
grade. Among all patients studied, the expression of HDAC1 and HDAC3 was inversely correlated with
survival, whereas the expression of HDAC4, HDAC5, HDAC6, HDAC11 and SIRT1 was significantly and
positively correlated with survival time of patients with gliomas. 1H-HRMAS technology revealed
metabolomically distinct groups according to the expression of HDAC1, HDAC4 and SIRT1, suggesting
that these genes may play an important role in regulating brain tumorigenesis and cancer progression. Our
study hence identified different molecular fingerprints for subgroups of histopathologically similar brain
tumors thatmay enable the prediction of outcome based on the expression level of co-factor genes and could
allow customization of treatment.
P
rimary brain tumors are notoriously heterogenous. The overallmortality rate for some tumor subtypes, such
as high-grade gliomas, remains high and only limited progress in survival has been achieved in the last
decades1. Furthermore, the responsiveness of patients to therapeutic protocols varies with no clear predict-
ive factor to determine treatment response. An in-depth dissection of the molecular basis of resistance to
treatment and the identification of specific signaling pathways that are involved in tumor development and
progression, are key in the search for a more targeted and effective therapies for brain tumors.
Perhaps equally important to the numerous genetic mutations, amplifications and deletions that accumulate in
a given tumor are epigenetic modifications2. One of the best-characterized epigenetic modifications is the
acetylation/deacetylation status of lysine residues in histones, which regulates gene transcription by controlling
chromatin unfolding (activation) and condensation (silencing), respectively. These two opposing processes are
regulated through histone acetyltransferases (HATs) and histone deacetylases (HDACs) (for review see Refs. 3–
5), respectively. The HDAC family of lysine deacetylases are homologs of the yeast Rpd3/Hda1 deacetylases and
contain 11 members termed HDAC1-11 that divide into 3 classes I, II and IV. Class III consists of the sirtuin
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family of HDACs represented by 7members (SIRT1-7) sharing a 270
aminoacid catalytic domain and a mandatory metabolic co-factor,
NAD1 (reviewed in Ref. 6).
Several HATs andHDACs have been implicated in tumorigenesis,
andHDAC inhibitors (HDACi) effectively inhibit tumor growth and
progression7,8 (a review). Class I and II HDACs are generally located
in the nucleus and are overexpressed in various cancers9,10
(reviews)11–15. Furthermore, class II and IV HDACs were recently
shown to be downregulated in glioblastomas16. A set of sirtuin genes,
including SIRT1, SIRT3 and SIRT7, are overexpressed in certain
cancers17 (a review). The role of SIRT1 in cancer is not fully under-
stood and remains controversial. For instance, when SIRT1 was
shown to suppress tumorigenesis in colon cancer growth through
deacetylation ofb-catenin18, SIRT1-knockdown significantly delayed
mitotic entry of glioma cells, inhibited cell growth and proliferation,
and promoted apoptosis19. In addition, SIRT1 knockdown sensitized
glioma cells to radiation-induced apoptosis20. Recently, SIRT1 was
suggested to mediate cell proliferation in gliomas through the con-
nection with the forkhead box M121. In line with the latest cited
studies, we have recently shown that specific intestinal loss of
SIRT1 protects from colitis-associated colorectal cancer22. Finally,
the expression of the « checkpoint » tubulin deacetylase SIRT2 was
reported to be reduced in gliomas23,24 and was shown to be required
for glioma stem cell proliferation arrest25.
Because of the genetic heterogeneity and the poor treatment
responsiveness, a diagnostic approach that establishes the molecular
signature for the tumor would be highly beneficial. To this end, we
measured the expression of the 18 known HDAC genes and of 6
genes encoding transciptional co-factors in 50 samples representing 3
histopathologically identified gliomas, namely W.H.O. (World Health
Organization) grade II oliodendrogliomas (ODII), grade III oliodendro-
gliomas (ODIII), grade IV glioblastoma (GL), and in 15 control brain
samples from epilepsia-operated patients. Cluster analysis of the gene
expression data enabled the identification of molecular subgroups of
tumors that were undistinguishable by histopathological methods.
Results
Expression pattern of HDACs in brain tumors by qRT-PCR. To
characterize the molecular fingerprint of brain tumors, we analyzed
by qRT-PCR the expression profile of all HDACs (class I–IV) and six
transcriptional co-factors in different brain tumor samples and
control brain tissues. All HDACs were expressed in non-tumoral
samples, and their expression was altered in many tumor types
(Figure 1). For clarity, the levels of significance are presented
separately in Table S2. The degree of increase in HDAC1
expression followed the grade of gliomas. HDAC1 levels were
significantly increased in ODIII and grade IV gliomas, while the
increase in ODII did not reach statistical significance. HDAC2 was
increased only in ODIII (1.9-fold, p 5 0.051). HDAC3 was
significantly increased only in malignant ODIII and GL gliomas.
HDAC4 was significantly increased in ODII and ODIII but the
expression in glioblastoma was heterogenous among this class of
patients and overall did not reach statistical significance (Figure 1
and Table S2). HDAC6 expression was significantly increased in all
grades of gliomas, whereas HDAC7 and HDAC10 were significantly
increased only in ODIII and GL tumors. HDAC8 and HDAC9
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Figure 1 | Quantitative expression of the 18 histone deacetylases (HDACs) and 6 metabolic cofactors in different human brain tumors as indicated.
The qRT-PCR data are presented as medians of the gene expression level normalized first to the 18S gene then to non-tumoral specimen (the median of
controls was set to 1). The boxplots represent the expression rates ranging from the lowest to the highest value. Outlier values are also represented.
www.nature.com/scientificreports
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expression levels were not significantly changed in gliomas as
compared to control patients. Among class I and II HDACs,
HDAC5 was particular and its expression was significantly
decreased in ODIII and GL tumors. Class IV HDAC11 seemed to
follow a tumor grade gradient in its decrease. Hence, HDAC11
expression was significantly decreased in ODIII tumors and
dramatically diminished in GL patients. The decrease in HDAC11
expression in ODII patients did not reach statistical significance.
Regarding the sirtuin family of class III HDACs, SIRT1 expression
was moderately but significantly increased in ODII and ODIII while
it was modestly diminished in GL, yet this decrease was not
statistically significant. SIRT2 expression was significantly
decreased in most of GL patients with the exception of one patient
who had an increased expression. SIRT2 expression was
heterogeneous in ODII and ODIII gliomas, a subset of patients
exhibiting a moderate increased expression, while most of them
had decreased expression levels. SIRT3 expression was significantly
decreased in the aggressive GL tumors but the decrease was not
significant in grade II and III gliomas. SIRT4 and SIRT5 expression
was decreased in most of the patients, but the decrease was not
statistically significant due to an increased expression in few
patients (Figure 1 and Figure 2). Conversely, SIRT6 expression was
moderately and significantly increased in all gliomas. As for SIRT7,
the modest increased expression in ODIII and GL tumors was not
statistically significant. Regarding the metabolic co-activators
PGC1a and PGC1b (encoded by the PPAGC1A and PPARGC1B
genes, respectively), PPARGC1A expression was significantly
increased in ODIII and GL tumors, whereas PPARGC1B
expression was robustly decreased in all gliomas. In average, the
decrease in PPARGC1B expression level followed a tumor gradient,
grade IV tumors exhibiting the lowest expression. Among the co-
repressors, only NCOR2/SMRT was significantly increased in ODIII
tumors. The expression of the tumor suppressor gene RB1 was
moderately increased in ODII tumors (p 5 0.06) and significantly
enhanced in grade III and IV gliomas (p , 0.01).
Cluster analysis of HDAC and NR co-factor expression profiles.
Cluster analysis is suited to identify groups of genes that are co-
regulated and potentially share functional commonalities.
Illustrating this principle, cluster analysis distinguished three main
groups of genes based on their expression levels in all tumor types,
regardless of the HDAC classification. Of particular note, non-
tumoral samples (CO) clustered together and were separated from
the tumor samples (Figure 2A). Gene cluster I represents genes that
were mostly down-regulated in a subgroup of gliomas (A2b),
including HDAC11, PPARGC1B, HDAC9, HDAC5, SIRT3, SIRT5,
NCOR1, HDAC8, SIRT4, and SIRT2. In subgroup B, two genes
HDAC11 and PPARGC1B were down-regulated in all tumors,
suggesting that these co-factors might regulate genes commonly
induced in tumorigenesis (e.g. anti-apoptotic and proliferation
genes, or genes involved in oxidative metabolism). Other cluster I
genes showed heterogeneous expression among the gliomas
belonging to this subgroup (Figure 2A). Gene cluster II represents
genes that were mostly overexpressed in a subgroup of tumors (B)
and include RB1, NCOR2, HDAC6, HDAC10, HDAC3, HDAC7 and
HDAC1. In this cluster, HDAC1 was the only gene that was induced
in almost all tumor samples, suggesting that HDAC1 play an
important role in brain tumorigenesis (Figure 2A). The metabolic
regulator PPARGC1A (subcluster IIa) was variably expressed among
tumors. Some tumors displayed a robust overexpression of
PPARGC1A while other samples showed a strong down-regulation
or only a modest change in expression. In addition, two genes SIRT1
and HDAC4 that clustered together (in gene cluster IIa) were
strongly overexpressed in two subgroups of tumors (B1a1 and B2)
but significantly down-regulated in most of the samples of subgroup
A2b.
Panels B to E in Figure 2 represent gene clusters in specific tumor
types (ODII, ODIII, ODs and GL). One can appreciate that genes
cluster differently in different tumor types that represent different
tumor grades, suggesting differentmolecular signatures for each type
or grade. Secondarily, some genes are overexpressed in a group of
patients while down-regulated or unchanged in others within the
same histopathologic entity, underscoring the molecular heterogen-
eity of tumors that are indistinguishable by histopathologic means.
Finally, within OD tumors, we observed that ODII tumors do not
necessarily form a distinguished cluster from ODIII tumors
(Figure 2D).
In summary, HDAC and co-factors gene expression levels dis-
criminate subgroups of patients that do not necessarily belong to
the same histopathologic grade (e.g. some ODIII cluster with GL
tumors, Figure 2A) and even within the same grade, molecular sub-
groups were identifiable, which challenges the histopathological clas-
sification and might explain why all glioma patients do not respond
equally to the available therapeutic protocols.
Pearson correlation between the expression level of HDACs and
cofactors among gliomas.We derived a heatmap from the gene-to-
gene Pearson correlations for the 24 HDACs/cofactors within our
qRT-PCR expression profiles in all gliomas, i.e. GL, ODII and ODIII
together (Figure 3A). Among the positively co-correlated genes,
HDAC1, HDAC3 and HDAC7 formed the clearest cluster. Other
clusters with positively co-correlated genes contained PPARGC1B
and HDAC11, both strongly down-regulated in gliomas (Figure 1),
and HDAC2, HDAC9 and SIRT6. Yet another major positively co-
correlated cluster was identified, containing two subclusters of
SIRT1, HDAC8, SIRT3 and NCOR1 genes on one hand and
HDAC6, HDAC4, NCOR2 and HDAC10 genes on the other. The
strongest correlation within this cluster was that between SIRT1
and HDAC4 genes. We also identified clusters of genes that were
negatively co-correlated among glioma patients. Hence, we
identified HDAC3, HDAC7 and HDAC1 that were found to be
robustly and negatively correlated with HDAC11, PPARGC1B,
SIRT2 and SIRT4, with the exception of SIRT4 and HDAC1 that
were not correlated. This was also the case, though to a lesser
extent, for the negative correlations found between the members of
the SIRT1, HDAC8 and SIRT3 cluster and the members of the
HDAC1, HDAC7 and HDAC3 cluster (Figure 3A). We then
analyzed the gene-to-gene correlations separately in the most
aggressive gliomas. Amongst the ODIII samples, the strongest
positive correlations were within cluster 1: SIRT1, HDAC4 and
HDAC10; cluster 2: HDAC6 and SIRT3; cluster 3: NCOR1 and
SIRT6; cluster 4: SIRT5, HDAC5 and HDAC8; and cluster 5:
HDAC9, HDAC3, HDAC2 and HDAC1 (Figure 3B). For GL, the
strongest positive correlations were within cluster 1: SIRT3,
NCOR1, HDAC5 and PPARGC1A; cluster 2: HDAC6 and HDAC8;
cluster 3: SIRT4 and SIRT7; and cluster 4:HDAC4, SIRT1, SIRT6 and
HDAC2 (Figure 3C). Of particular note, also RB1, NCOR2 and
HDAC9 were positively correlated indicating that these genes
might interact and participate in the pathogenesis of glioblastoma.
These gene-to-gene correlations among HDACs and cofactors
might reveal transcriptional cues for other genes involved in a par-
ticular signaling pathway involved in the pathogenesis of these
tumors. Other experiments are needed to verify the potential phys-
ical interaction between the co-correlated genes in the context of
brain tumorigenesis.
Correlation of gene expression profile of HDACs and cofactors
with survival of patients with gliomas. In order to evaluate the
potential for the analyzed 24 HDAC and cofactor genes to serve as
markers of how aggressive the gliomas are, we correlated the tumor
expression profiles of these genes with the survival time of those 40
patients from whom the tumor samples were obtained (and whom
had died during the study period). Of all the genes studied, HDAC1
www.nature.com/scientificreports
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Figure 2 | (A) Unsupervised hierarchical clustering of HDAC and metabolic cofactor gene expression profiles in human brain tumor and non-tumoral
(controls) samples. Subgroups identified by cluster analysis are highlighted by horizontal lines for genes and by vertical lines for brain tumor samples.
Increased gene expression is represented by the red color and decreased expression in blue. The intensity of the color represents the degree of expression.
The same clustering analysis was performed separately for ODII tumor samples (B), ODIII (C), ODII and ODIII together (D) and GL (E).
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and HDAC3 were inversely and significantly correlated with the
survival of patients with gliomas, when analyzed collectively (p 5
0.002 and p 5 0.016 respectively, Figure 4). RB1 expression levels
tended to correlate negatively with survival of patients, although the
correlation did not reach statistical significance (p5 0.072, Figure 4).
HDAC4, HDAC5, HDAC6 and HDAC11 expression levels were
positively correlated with survival (p 5 0.001, p 5 0.007, p 5 0.04
and p 5 0.001 respectively, Figure 4). Among the sirtuin family of
HDACs, only SIRT1 correlated significantly with the survival of
patients (p 5 0.034, Figure 4), while a tendency for SIRT3 was
observed (p 5 0.053, Figure 4).
Interestingly, when samples were analyzed separately based on
tumor grade,HDAC11 expression levels correlated significantly with
survival time among GL patients (p 5 0.004, n 5 15) but not among
ODIII patients (p 5 0.198, n 5 20), suggesting that the decreased
expression of HDAC11 in grade IV tumors (i.e. GL) may have a
greater impact on tumor aggressiveness and clinical outcome than
in the less aggressive grade III oligodendroglioma. Of note, when
analyzing ODIII and GL together, HDAC11 still correlated with
survival time of patients (p 5 0.009, n 5 35). As for HDAC4 and
HDAC6, the opposite was observed. These genes were correlated
with survival time in ODIII patients (p 5 0.006 for HDAC4 and p
5 0.047 for HDAC6, n 5 20) but they did not in GL patients (p 5
0.552 for HDAC4 and p 5 0.381 for HDAC6, n 5 15), suggesting
that HDAC4 and HDAC6 may play a greater role in ODIII tumor
aggressiveness than in GL tumors.
We then analyzed the mean survival times of patients between the
tumor grades. As expected, we observed a clear inverse relationship
between the grade of the tumor and the survival time (Figure 5).
Interestingly, based on the survival time of patients, the ODIII group
was heterogeneous and divided in two groups. One subgroup had a
high survival time with an average survival time similar to that of the
ODII group (surrounded by the orange dashed ellipse in Figure 5),
the second group had a low survival time (red dashed ellipse in
Figure 5) similar to the GL patients and even more aggressive in
average to the mean survival time of GL.
From this survival analysis, we can conclude that of all the HDACs
and co-factors analyzed, the expression levels of only a subset of
genes correlated significantly with the post-surgery survival time of
glioma patients who died during the study period. Furthermore,
tumor aggressiveness and survival may be significantly affected by
the expression of just one gene (HDAC11 in GL and HDAC4 and
HDAC6 in ODIII). Finally, the molecular heterogeneity observed in
cluster analysis amongst OD tumors, together with the fact that the
mean survival time of a subgroup of ODIII was similar to ODII
patients, suggests that the histopathological classification of patients
with gliomas does not necessarily follow the level of aggressiveness of
the tumors.
1H-HRMAS analysis of brain tumors. We used a metabolomic
approach to compare the metabolomic profile of tumors based on
their histological grade then on the assignation to differentmolecular
subtypes for genes that were correlated to survival time among
glioma patients. We will present only meaningful results. The
statistical significance of the different group comparisons was
assessed by the partial least square discriminant analysis (PLS-DA)
statistical model, a supervised analysis procedure that maximizes the
separation between classes based on their metabolomic profile. PLS-
DA models were built for each hypothesis using the most
discriminating binned variables (e.g. with a variable of importance
Correlation
Correlation
Correlation
A
B
C
Figure 3 | Pairwise-Pearson correlation (PPC) analysis of HDACs and
co-factors in glioma samples. Unsupervised hierarchical clustering was
carried out on pairwise Pearson gene-to-gene correlations using
heatmap.2 from the R package gplots. Correlation coefficient equal to 1
represents the correlation of each gene to itself and is shown in red with the
highest intensity. Negative correlations are shown in a light (poor
correlation) to dark (strong correlation) blue color scale. The analysis was
performed for all tumors together (GL, ODII andODIII) (A), or separately
for ODIII (B) and GL (C).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9087 | DOI: 10.1038/srep09087 5
value superior to the cut off of 1.0) corresponding to the most
discriminating metabolites among the following list: Glycine (Gly),
glutamate, aspartate, serine, N-acetyl aspartate, acetate, succinate,
glycerophosphocholine (GPChol), phosphocholine (PChol),
lactate, isoleucine, valine, reduced glutathione (GSH), creatine
(Cr), ascorbate, lysine, myo-inositol (MyoI), alanine, taurine and
glutamine. We presented in Figure 6A a quantification of the
following metabolites, which concentrations have been shown to
vary significantly in high grade brain tumors as compared to low
grade tumors: PChol, GPChol, Gly, MyoI and Cr26–28. We observed
that as the grade of tumor increased the GPChol/PChol ratio, MyoI
and Cr decreased significantly, whereas Gly and Gly/MyoI ratio were
significantly increased (Figure 6A). Since a decreased GPChol/PChol
ratio seems to be associated with an increased malignancy and that
the expression of some HDACs was correlated with survival, we
stratified patients based on the expression of HDAC1, HDAC4 and
SIRT1 regardless of tumor grade and compared their metabolomic
profiles. Given that all GL patients had an increased HDAC1
expression level, we ran the hypothesis only for ODs. We observed
that OD samples with high HDAC1 expression formed a metabolo-
mically distinct group from patients with unchanged (NC 5 not
changed) HDAC1 expression, the former having a significantly
lower GPChol/PChol ratio (Figure 6B). Along the same line,
glioma samples (ODs and GL) with high HDAC4 and SIRT1
expression were metabolomically different from samples with low
HDAC4 and SIRT1 expression, the latter having a significantly lower
GPChol/PChol ratio than the former group (Figure 6C and 6D,
respectively). Of interest, we observed that the GPChol/PChol ratio
correlated with survival time among our glioma patients (Figure 6E).
Also, this ratio was negatively and positively correlated withHDAC1
and HDAC4 expression, respectively while the correlation with
SIRT1 expression did not reach statistical significance (Figure 6E).
Altogether, metabolomic data suggest that a decreased GPChol/
PChol ratio is associated with high-grade tumors and that the
expression of HDAC1, HDAC4 and SIRT1 may influence tumor
aggressiveness through changes in metabolomic profiles of tumors.
Discussion
The expression analysis of the 18 known HDACs and a subset of 6
transcriptional regulators in 50 brain tumors samples obtained from
patients operated from grade II–IV gliomas, and 15 non-tumoral
samples allowed us to discriminate brain tumors with indistinguish-
able histopathological features by their different molecular « finger-
prints ». The relevance of studying the expression of HDACs in brain
tumors lies in the fact that their overexpression has been documented
in several cancers, and some HDAC inhibitors have shown clinical
efficacy for the treatment of some cancers29–31. Of particular note,
HDAC5 was the only class II member whose expression was reduced
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Figure 4 | Correlation of relative gene expression levels in glioma tumor samples to the time of survival of patients.Correlations that reached statistical
significance are in bold.
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in most tumors studied here (Figure 2A) and robustly so in all of our
glioblastoma samples (Figure 2E). Interestingly,HDAC5 overexpres-
sion in tumor cell lines has been shown to blunt tumor growth and
promote apoptosis through the extrinsic pathway32, underpinning
the tumor suppressor potential for HDAC5. In addition, we found a
strong positive correlation between HDAC5 expression levels and
survival time of patients with gliomas (Figure 4), strengthening the
notion that HDAC5 may be an important factor in the epigenetic
control of genes involved in tumor growth and apoptosis of cancer
cells. Even though the expression level for HDAC4 did not vary
within the GL tumors, the expression ofHDAC4 correlates positively
with a better survival time across all tumor samples (Figures 4). The
biological significance of this observation needs further clarification.
Consistent with a recent study showing that class IVHDAC11was
strongly down-regulated in GL tumors16, we found the expression of
HDAC11 diminished in all tumor samples, especially those with high
grade of malignancy. In addition, we found thatHDAC11 expression
levels correlated significantly with the survival time of patients with
gliomas (all tumor samples combined). This was mainly the case for
the most aggressive GL, as HDAC11 expression level was not corre-
lated with the survival time amongst ODIII patients, which could be
due to the scattered distribution of survival time in the ODIII group
(see Figure 5). In average, HDAC11 expression decreased with the
increase in the grade of the tumor (Figure 1). It has been reported that
the disruption of HDAC11 in antigen presenting cells (APCs)
induces the expression of IL10 and subsequently impairs antigen-
specific T cell responses33. These data suggest that HDAC11 may
have an important role in modulating the immune response against
gliomas, thereby promoting tumor growth suppression. Hence,
HDAC11 inhibition below a certain threshold may not be sufficient
to the immune system to fight against the tumor, which therefore
becomes more aggressive affecting thereby the survival time of
patients. Of particular note, it has been shown recently that
HDAC6 and HDAC11, which were expressed in opposite manner
in our glioma samples (HDAC6 overexpressed and HDAC11 down-
regulated), have divergent roles on the transcriptional regulation of
IL10 in antigen presenting cells34,35. In view of our data and given the
role of HDAC11 in antigen-specific T cell responses, we suggest that
restoring HDAC11 expression levels to normal values (e.g. through
lentiviral-mediated gene therapy) may improve the survival of
patients with gliomas, especially GL.
Regarding the SIRT genes, we observed that expression of the
mitochondria-localized SIRT3 was significantly downregulated in
GL tumors in average, albeit not in all samples, suggesting a potential
role of SIRT3 as a discriminant gene in the molecular signature of
brain tumors. SIRT3 was previously described as a tumor suppressor
gene, whose suppression induced an increase in glycolysis and a
decrease in oxidative phosphorylation36. This is consistent with a
potential anti-Warburg effect37 of SIRT3, knowing that aggressive
tumors consume glucose at a higher rate than less aggressive ones
to generate ATP. Interestingly, we found a modest positive correla-
tion of SIRT3 expression with survival of patients. This could be
ascribed to the decreased expression of SIRT3 in highly aggressive
GL tumors (Figure 4).
Of particular interest, we found that SIRT1 and HDAC4 co-
correlate in GL and in ODIII, suggesting that these genes cooperate
to regulate a yet to be identified target gene or gene set. Two tran-
scription factors, myocyte enhancer factor 2 (MEF2), involved in
skeletal muscle differentiation, and hypermethylated in cancer 1
(HIC1), silenced in many human cancers, are regulated by SIRT1
and HDAC4 through deacetylation and sumoylation, respect-
ively38,39. We showed that samples with overexpressed HDAC4
and/or SIRT1 were associated with an increased GPChol/PChol
ratio. An increased choline kinase (which enhances PChol levels)
and glycerophosphodiesterase activities (which decreases GPChol
levels) have been linked to enhanced tumorigenesis and cancer cell
migration40–42. These observations suggest that SIRT1 and HDAC4
may regulate the choline pathway to block tumorigenesis limiting
thereby tumor aggressiveness and that their downregulation might
predict a bad prognosis in gliomas patients.
It is known that reactive oxygen species (ROS)-mediated mtDNA
mutations are associated with malignant cancer progression43.
Overexpression of PGC-1 cofactors (a and b) was reported to protect
cells against ROS by up-regulating anti-oxidant defense mechan-
isms44. It is tempting to speculate that the decrease in PPARGC1B
observed in our brain tumor samples could participate in the increase
in ROS formation and eventually impact on mtDNA mutations.
However, the increase in the other PPARGC1, namely PPARGC1A,
could be a compensatory mechanism to mitigate the PPARGC1B
decrease and hence restrain ROS formation. Moreover,
PPARGC1A and PPARGC1B have been shown to protect neurons
from mitochondrial loss and oxidative damage45. Interestingly,
PPARGC1A expression was differentially affected within our tumor
sample of the same histopathological entity. The pathophysiological
relevance of this differential expression in PPARGC1A needs to be
determined. It is worth mentioning that we did not find any correla-
tion between PPARGC1A and PPARGC1B expression and survival
time of patients (Figure 4).
In conclusion, cluster analysis of the 24 genes encoding histone
deacetylases and select metabolic regulators in patients with brain
glioma tumors allowed us to group genes according to their express-
ion profiles, and facilitated the discrimination of subtypes of primary
brain tumors within the same histopathological entity. Furthermore,
we found that pairwise Pearson gene-to-gene correlation identified
clusters of genes thatmight cooperate to regulate a yet to be identified
signaling pathway(s) in gliomas. We also identified thatHDAC1 and
HDAC3 expression levels were negatively correlated with survival
time among glioma patients, whereas the expression of HDAC4,
HDAC5,HDAC6,HDAC11 and SIRT1was positively correlated with
survival time of patients with gliomas. In addition, HRMAS data
revealed that patients with the expression profile HDAC1high/
HDAC4low/SIRT1low present a decreased GPChol/PChol ratio, a
metabolomic hallmark of aggressive brain tumors, while those with
a HDAC1NC/HDAC4high/SIRT1high expression profile had signifi-
Figure 5 | Mean survival time in patients with grade II, III and IV
gliomas. The survival time was determined from the time of surgery until
the death of the patient. The orange dashed ellipse represents a
distinguished set of histopathological classified ODIII patients whose
survival time were much higher from the rest of ODIII patients with poor
survival time (red ellipse; some of these tumors were even more aggressive
than some grade IV GL tumors). * p , 0.05, ** p , 0.01.
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Figure 6 | 1H-HRMAS NMR spectroscopy analysis of grade II–IV gliomas. (A) HRMAS-measured glycerophosphocholine (GPChol), phosphocholine
(PChol), glycine (Gly), myo-inositol (MyoI) and creatine (Cr) metabolites in grade II (ODII, n 5 9), grade III (ODIII, n 5 19) and grade IV
(glioblastoma, GL, n 5 17). The GPChol/PChol and Gly/MyoI ratios are also presented. (B) Results of two-component PLS-DA model built on the
following metabolites: Glycine (Gly), glutamate, aspartate, serine, N-acetyl aspartate, acetate, succinate, glycerophosphocholine (GPChol),
phosphocholine (PChol), lactate, isoleucine, valine, reduced glutathione (GSH), creatine (Cr), ascorbate, lysine, myo-inositol (MyoI), alanine, taurine
and glutamine among oligodendrogliomas (ODII and ODIII) according HDAC1 expression level. HDAC1-overexpressing tumors (HDAC1 Up, red
dots) and samples with unchanged HDAC1 expression (HDAC1NC, blue triangles) formedmetabolomically distinct classes. (C). Results of 2-class PLS-
DA model among gliomas (regardless of tumor grade) according to HDAC4 expression level. HDAC4-overexpressing samples (HDAC4 Up, red dots)
and samples with downregulated HDAC4 (HDAC4 Do, blue triangles) form two different groups. (D) 2-class PLS-DA model according to SIRT1
expression level in glioma samples. SIRT1-overexpressing samples (SIRT1 Up, red dots) and samples with downregulated SIRT1 (SIRT1 Do, blue
triangles) form distinct groups. A zoomof representative spectra indicating the intensity of GPChol, PChol and choline (Cho) as well as the quantification
of the GPChol/PChol ratio in each model are presented (B, C and D). E) Correlation of survival time, HDAC1, HDAC4 and SIRT1 expression with
GPChol/PChol ratio among gliomas.
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cantly higher GPChol/PChol ratio associated with low grade tumors.
Concomitant inhibition ofHDAC1 and activation ofHDAC4/SIRT1
may be salutary in restraining highly aggressive tumor progression
and may improve survival time in glioma patients.
A better understanding of how HDACs and metabolic cofactors
interact to regulate important genes involved in the pathogenesis of
high grade gliomas will help design newmolecular therapeutic agents
to improve the survival of patients and perhaps even cure these
deadly diseases. Another challenge is to unravel why patients belong-
ing to the same histo-pathological entity express differentially a sub-
set of HDACs and cofactors, and how this difference in gene
expression influence the aggressiveness of the tumor and thereby
survival of patients. Our study has begun to answer these questions,
thereby paving the way to the establishment of a molecular « finger-
print » of gliomas as a guide to new therapeutic approaches.
Patients and Methods
Patients. Patients undergoing surgical resection of brain tumors were from the
Department of Neurosurgery (Strasbourg University Hospital). Informed written
consent was obtained from all patients studied and the study complies with the
Helsinki declaration. The protocol was approved by the ethical committee of
protection of persons (‘‘Comite´ de Protection des Personnes’’) at the Strasbourg
University Hospital (CPP approval number 03/100). Cerebral glioma tumor samples
from 50 patients, classified on the basis of the four (I–IV) histo-prognostic grades
established by theWorld Health Organization (WHO), were compared with 15 non-
tumoral brain samples from patients operated for epilepsia (CO; n 5 15, 30.8 6
3.2 yrs). Tumor types included grade II oligodendrogliomas (ODII; n 5 9, 39.1 6
3.5 yrs), grade III oligodendrogliomas III (ODIII; n 5 22, 44.6 6 2.5 yrs) and
glioblastomas (GL/grade IV; n 5 19, 57.6 6 2.9 yrs). The survival time of operated
patients was followed from August 2003 until November 2013, during which 40
patients died (ODII: 5, ODIII: 20, GL: 15).
qRT-PCR analysis for gene expression profile and cluster analysis.HDACandNR-
cofactor gene expression profiles were established by qRT-PCR on a Lightcycler
LC480 (RocheH) and then hierarchically clustered as described46. The primer sets
used for qRT-PCR analysis are shown in Table S1.
1H-high resonance magic angle spectroscopy ( 1H-HRMAS) analysis. Brain tumor
samples were collected with minimum ischemic delays after resection (average time
5 min) and snap-frozen in liquid nitrogen before being stored at 280uC. Biopsy
samples (About 20 mg) were prepared at 210uC and introduced into a disposable
30 ml KelF insert. HRMAS spectra were recorded on a Bruker Avance III 500
spectrometer operating at a proton frequency of 500.13 MHz and equipped with a
4 mm double resonance ( 1H, 13C) gradient HRMAS probe as described47.
Statistics. For gene expression levels, the differences between tumors and control
samples were considered statistically significant at p, 0.05 using unpaired t-test. The
gene expression level was correlated with survival time of patients using regression
analysis. Regarding the survival time, the GL/ODII and ODIII/ODII comparisons
were considered statistically significant at p, 0.05 using Mann-Whitney test and the
GL/ODIII comparison using an unpaired t-test. Cluster analysis and Pearson’s
correlation coefficients were determined using TMEV 4.1.01 software (www.tm4.
org). Boxplots were generated using the R software andGraphPad Prism 6.0.Multiple
comparisons of metabolite quantification among ODII, ODIII and GL in HRMAS
analysis were considered statistically significant at p, 0.05 using ANOVA followed
by Kruskal-Wallis test.
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